Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 STUDY TO EVALUATE THE EFFECTS OF MULTIPLE DOSES OF LY3537982 ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, DIGOXIN, AND ROSUVASTATIN IN HEALTHY ADULT SUBJECTS

NCT06111521 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06111521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06111521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 STUDY TO EVALUATE THE EFFECTS OF MULTIPLE DOSES OF LY3537982 ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, DIGOXIN, AND ROSUVASTATIN IN HEALTHY ADULT SUBJECTS
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
October 27, 2023
Completion date
April 1, 2024
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy